{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Run this cell: \n",
    "# The lines below will instruct jupyter to reload imported modules before \n",
    "# executing code cells. This enables you to quickly iterate and test revisions\n",
    "# to your code without having to restart the kernel and reload all of your \n",
    "# modules each time you make a code change in a separate python file.\n",
    "\n",
    "%load_ext autoreload\n",
    "%autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/Users/shloknatarajan/stanford/research/daneshjou/AutoGKB\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "\n",
    "# Change path to project root\n",
    "if os.getcwd().endswith(\"notebooks\"):\n",
    "    os.chdir(os.path.dirname(os.getcwd()))\n",
    "print(os.getcwd())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import os\n",
    "from tqdm import tqdm\n",
    "import pickle\n",
    "from loguru import logger\n",
    "import json"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Articles to get\n",
    "- 3: Articles with only one annotation\n",
    "- 3: Articles with 2 annotations\n",
    "- 1: Article with all 3 annotations"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# load annotations_by_pmcid\n",
    "annotations_by_pmcid = pickle.load(open(\"data/variantAnnotations/annotations_by_pmcid.pkl\", \"rb\"))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Only One Annotation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5021"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "only_drug = []\n",
    "for pmid_addition in annotations_by_pmcid:\n",
    "    if len(pmid_addition[\"var_drug_ann\"]) > 0 and len(pmid_addition[\"var_fa_ann\"]) == 0 and len(pmid_addition[\"var_pheno_ann\"]) == 0:\n",
    "        only_drug.append(pmid_addition)\n",
    "len(only_drug)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "368"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "only_fa = []\n",
    "for pmid_addition in annotations_by_pmcid:\n",
    "    if len(pmid_addition[\"var_drug_ann\"]) == 0 and len(pmid_addition[\"var_fa_ann\"]) > 0 and len(pmid_addition[\"var_pheno_ann\"]) == 0:\n",
    "        only_fa.append(pmid_addition)\n",
    "len(only_fa)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5857"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "only_pheno = []\n",
    "for pmid_addition in annotations_by_pmcid:\n",
    "    if len(pmid_addition[\"var_drug_ann\"]) == 0 and len(pmid_addition[\"var_fa_ann\"]) == 0 and len(pmid_addition[\"var_pheno_ann\"]) > 0:\n",
    "        only_pheno.append(pmid_addition)\n",
    "len(only_pheno)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Two Annotations and All Three"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Two annotations: 2249\n",
      "All three annotations: 28\n"
     ]
    }
   ],
   "source": [
    "two_annotations = []\n",
    "all_three_annotations = []\n",
    "for pmid_addition in annotations_by_pmcid:\n",
    "    annotation_count = 0\n",
    "    if len(pmid_addition[\"var_drug_ann\"]) > 0:\n",
    "        annotation_count += 1\n",
    "    if len(pmid_addition[\"var_fa_ann\"]) > 0:\n",
    "        annotation_count += 1\n",
    "    if len(pmid_addition[\"var_pheno_ann\"]) > 0:\n",
    "        annotation_count += 1\n",
    "    if annotation_count == 2:\n",
    "        two_annotations.append(pmid_addition)\n",
    "    elif annotation_count == 3:\n",
    "        all_three_annotations.append(pmid_addition)\n",
    "print(f\"Two annotations: {len(two_annotations)}\")\n",
    "print(f\"All three annotations: {len(all_three_annotations)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Save all to new json files\n",
    "with open(\"data/variantAnnotations/exploration/two_annotations.json\", \"w\") as f:\n",
    "    json.dump(two_annotations, f)\n",
    "with open(\"data/variantAnnotations/exploration/all_three_annotations.json\", \"w\") as f:\n",
    "    json.dump(all_three_annotations, f)\n",
    "with open(\"data/variantAnnotations/exploration/only_drug.json\", \"w\") as f:\n",
    "    json.dump(only_drug, f)\n",
    "with open(\"data/variantAnnotations/exploration/only_fa.json\", \"w\") as f:\n",
    "    json.dump(only_fa, f)\n",
    "with open(\"data/variantAnnotations/exploration/only_pheno.json\", \"w\") as f:\n",
    "    json.dump(only_pheno, f)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## One of each study type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "study_types = {\n",
    "    \"cohort\": [],\n",
    "    \"case_control\": [],\n",
    "    \"case_series\": [],\n",
    "    \"cross_sectional\": [],\n",
    "    \"clinical_trial\": [],\n",
    "    \"meta_analysis\": [],\n",
    "    \"GWAS\": [],\n",
    "    \"replication\": [],\n",
    "    \"prospective\": [],\n",
    "    \"retrospective\": [],\n",
    "    \"linkage\": [],\n",
    "    \"other\": []   \n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'pmid': 29238301,\n",
       " 'pmcid': 'PMC5712579',\n",
       " 'title': 'Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population',\n",
       " 'study_parameters': {'Study Parameters ID': 1449169927,\n",
       "  'Variant Annotation ID': 1449169911,\n",
       "  'Study Type': 'case/control',\n",
       "  'Study Cases': 15.0,\n",
       "  'Study Controls': 50.0,\n",
       "  'Characteristics': 'SCAR, MPE, SJS (cases and controls)',\n",
       "  'Characteristics Type': 'Disease',\n",
       "  'Frequency In Cases': 0.06,\n",
       "  'Allele Of Frequency In Cases': '*35:08',\n",
       "  'Frequency In Controls': 0.001,\n",
       "  'Allele Of Frequency In Controls': '*35:08',\n",
       "  'P Value': '= 0.231',\n",
       "  'Ratio Stat Type': 'OR',\n",
       "  'Ratio Stat': 10.45,\n",
       "  'Confidence Interval Start': 0.4,\n",
       "  'Confidence Interval Stop': 270.41,\n",
       "  'Biogeographical Groups': 'East Asian',\n",
       "  'PMID': 29238301},\n",
       " 'var_drug_ann': [],\n",
       " 'var_fa_ann': [],\n",
       " 'var_pheno_ann': [{'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan}]}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "annotations_by_pmcid[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "all_study_types = set()\n",
    "for annotation in annotations_by_pmcid:\n",
    "    study_type = annotation[\"study_parameters\"][\"Study Type\"]\n",
    "    all_study_types.add(study_type)\n",
    "\n",
    "# remove nan from all_study_types\n",
    "all_study_types = list({t for t in all_study_types if pd.notna(t)})\n",
    "all_study_types.sort()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GWAS\n",
      "GWAS, prospective\n",
      "GWAS, replication\n",
      "GWAS, retrospective\n",
      "case series\n",
      "case series, clinical trial\n",
      "case series, linkage, trios\n",
      "case series, trios\n",
      "case/control\n",
      "case/control, GWAS\n",
      "case/control, GWAS, retrospective\n",
      "case/control, case series\n",
      "case/control, clinical trial\n",
      "case/control, clinical trial, GWAS\n",
      "case/control, clinical trial, meta-analysis\n",
      "case/control, clinical trial, prospective\n",
      "case/control, clinical trial, retrospective\n",
      "case/control, meta-analysis\n",
      "case/control, meta-analysis, GWAS\n",
      "case/control, prospective\n",
      "case/control, replication\n",
      "case/control, replication, retrospective\n",
      "case/control, retrospective\n",
      "clinical trial\n",
      "clinical trial, GWAS\n",
      "clinical trial, meta-analysis\n",
      "clinical trial, meta-analysis, GWAS\n",
      "clinical trial, meta-analysis, replication\n",
      "clinical trial, prospective\n",
      "clinical trial, replication\n",
      "clinical trial, replication, prospective\n",
      "clinical trial, retrospective\n",
      "cohort\n",
      "cohort, GWAS\n",
      "cohort, GWAS, prospective\n",
      "cohort, GWAS, replication\n",
      "cohort, GWAS, retrospective\n",
      "cohort, case series\n",
      "cohort, case series, prospective\n",
      "cohort, case/control\n",
      "cohort, case/control, GWAS\n",
      "cohort, case/control, replication\n",
      "cohort, case/control, retrospective\n",
      "cohort, clinical trial\n",
      "cohort, clinical trial, meta-analysis\n",
      "cohort, clinical trial, prospective\n",
      "cohort, clinical trial, retrospective\n",
      "cohort, cross sectional, retrospective\n",
      "cohort, linkage\n",
      "cohort, meta-analysis\n",
      "cohort, meta-analysis, GWAS\n",
      "cohort, meta-analysis, retrospective\n",
      "cohort, prospective\n",
      "cohort, prospective, retrospective\n",
      "cohort, replication\n",
      "cohort, replication, prospective\n",
      "cohort, replication, retrospective\n",
      "cohort, retrospective\n",
      "cohort, trios\n",
      "cross sectional\n",
      "cross sectional, retrospective\n",
      "linkage\n",
      "linkage, trios\n",
      "meta-analysis\n",
      "meta-analysis, GWAS\n",
      "meta-analysis, GWAS, replication\n",
      "meta-analysis, GWAS, retrospective\n",
      "meta-analysis, replication\n",
      "meta-analysis, retrospective\n",
      "prospective\n",
      "prospective, retrospective\n",
      "replication\n",
      "replication, prospective\n",
      "replication, retrospective\n",
      "retrospective\n",
      "retrospective, linkage, trios\n",
      "trios\n"
     ]
    }
   ],
   "source": [
    "for x in all_study_types:\n",
    "    print(x)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Analyzing annotation study types: 100%|██████████| 13523/13523 [00:00<00:00, 1573882.37it/s]\n"
     ]
    }
   ],
   "source": [
    "annotations_by_study_type = {}\n",
    "for annotation in tqdm(annotations_by_pmcid, desc=\"Analyzing annotation study types\"):\n",
    "    annotation_study_type = annotation[\"study_parameters\"][\"Study Type\"]\n",
    "    if pd.isna(annotation_study_type):\n",
    "        annotation_study_type = \"nan\"\n",
    "    if annotation_study_type not in annotations_by_study_type:\n",
    "        annotations_by_study_type[annotation_study_type] = []\n",
    "    annotations_by_study_type[annotation_study_type].append(annotation)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GWAS: 400\n",
      "GWAS, prospective: 7\n",
      "GWAS, replication: 3\n",
      "GWAS, retrospective: 9\n",
      "case series: 299\n",
      "case series, clinical trial: 3\n",
      "case series, linkage, trios: 1\n",
      "case series, trios: 1\n",
      "case/control: 1473\n",
      "case/control, GWAS: 97\n",
      "case/control, GWAS, retrospective: 7\n",
      "case/control, case series: 1\n",
      "case/control, clinical trial: 26\n",
      "case/control, clinical trial, GWAS: 3\n",
      "case/control, clinical trial, meta-analysis: 2\n",
      "case/control, clinical trial, prospective: 27\n",
      "case/control, clinical trial, retrospective: 9\n",
      "case/control, meta-analysis: 58\n",
      "case/control, meta-analysis, GWAS: 17\n",
      "case/control, prospective: 8\n",
      "case/control, replication: 30\n",
      "case/control, replication, retrospective: 2\n",
      "case/control, retrospective: 78\n",
      "clinical trial: 502\n",
      "clinical trial, GWAS: 51\n",
      "clinical trial, meta-analysis: 6\n",
      "clinical trial, meta-analysis, GWAS: 2\n",
      "clinical trial, meta-analysis, replication: 1\n",
      "clinical trial, prospective: 64\n",
      "clinical trial, replication: 34\n",
      "clinical trial, replication, prospective: 13\n",
      "clinical trial, retrospective: 76\n",
      "cohort: 6357\n",
      "cohort, GWAS: 212\n",
      "cohort, GWAS, prospective: 12\n",
      "cohort, GWAS, replication: 2\n",
      "cohort, GWAS, retrospective: 16\n",
      "cohort, case series: 2\n",
      "cohort, case series, prospective: 2\n",
      "cohort, case/control: 69\n",
      "cohort, case/control, GWAS: 2\n",
      "cohort, case/control, replication: 2\n",
      "cohort, case/control, retrospective: 1\n",
      "cohort, clinical trial: 167\n",
      "cohort, clinical trial, meta-analysis: 4\n",
      "cohort, clinical trial, prospective: 6\n",
      "cohort, clinical trial, retrospective: 4\n",
      "cohort, cross sectional, retrospective: 4\n",
      "cohort, linkage: 1\n",
      "cohort, meta-analysis: 21\n",
      "cohort, meta-analysis, GWAS: 9\n",
      "cohort, meta-analysis, retrospective: 1\n",
      "cohort, prospective: 275\n",
      "cohort, prospective, retrospective: 2\n",
      "cohort, replication: 36\n",
      "cohort, replication, prospective: 6\n",
      "cohort, replication, retrospective: 1\n",
      "cohort, retrospective: 348\n",
      "cohort, trios: 1\n",
      "cross sectional: 19\n",
      "cross sectional, retrospective: 2\n",
      "linkage: 13\n",
      "linkage, trios: 2\n",
      "meta-analysis: 543\n",
      "meta-analysis, GWAS: 90\n",
      "meta-analysis, GWAS, replication: 1\n",
      "meta-analysis, GWAS, retrospective: 1\n",
      "meta-analysis, replication: 17\n",
      "meta-analysis, retrospective: 29\n",
      "nan: 1322\n",
      "prospective: 270\n",
      "prospective, retrospective: 6\n",
      "replication: 112\n",
      "replication, prospective: 1\n",
      "replication, retrospective: 12\n",
      "retrospective: 200\n",
      "retrospective, linkage, trios: 1\n",
      "trios: 9\n"
     ]
    }
   ],
   "source": [
    "# sort keys of annotations_by_study_type\n",
    "annotations_by_study_type = dict(sorted(annotations_by_study_type.items()))\n",
    "\n",
    "# print number of annotations in each study type\n",
    "for study_type, annotations in annotations_by_study_type.items():\n",
    "    print(f\"{study_type}: {len(annotations)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Save annotations_by_study_type to json\n",
    "# with open(\"data/variantAnnotations/exploration/annotations_by_study_type.json\", \"w\") as f:\n",
    "#     json.dump(annotations_by_study_type, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "annotation_template = {\n",
    "    \"pmid\": None,\n",
    "    \"pmcid\": None,\n",
    "    \"study_parameters\": [],\n",
    "    \"var_drug_ann\": [],\n",
    "    \"var_fa_ann\": [],\n",
    "    \"var_pheno_ann\": [],\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "13523"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(annotations_by_pmcid)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Grouping annotations by PMID: 100%|██████████| 13523/13523 [00:00<00:00, 592464.33it/s]\n"
     ]
    }
   ],
   "source": [
    "annotations_pmid_grouped = {}\n",
    "for annotation in tqdm(annotations_by_pmcid, desc=\"Grouping annotations by PMID\"):\n",
    "    annotation_pmcid = annotation[\"pmid\"]\n",
    "    if pd.isna(annotation_pmcid):\n",
    "        annotation_pmcid = \"nan\"\n",
    "    if annotation_pmcid not in annotations_pmid_grouped:\n",
    "        annotations_pmid_grouped[annotation_pmcid] = {\n",
    "            \"pmid\": None,\n",
    "            \"pmcid\": None,\n",
    "            \"study_parameters\": [],\n",
    "            \"var_drug_ann\": [],\n",
    "            \"var_fa_ann\": [],\n",
    "            \"var_pheno_ann\": [],\n",
    "        }\n",
    "    annotations_pmid_grouped[annotation_pmcid][\"pmid\"] = annotation.get(\"pmid\", None)\n",
    "    annotations_pmid_grouped[annotation_pmcid][\"pmcid\"] = annotation.get(\"pmcid\", None)\n",
    "    annotations_pmid_grouped[annotation_pmcid][\"study_parameters\"].append(annotation.get(\"study_parameters\", None))\n",
    "    annotations_pmid_grouped[annotation_pmcid][\"var_drug_ann\"].extend(annotation.get(\"var_drug_ann\", []))\n",
    "    annotations_pmid_grouped[annotation_pmcid][\"var_fa_ann\"].extend(annotation.get(\"var_fa_ann\", []))\n",
    "    annotations_pmid_grouped[annotation_pmcid][\"var_pheno_ann\"].extend(annotation.get(\"var_pheno_ann\", []))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'pmid': 29238301,\n",
       " 'pmcid': 'PMC5712579',\n",
       " 'study_parameters': [{'Study Parameters ID': 1449169927,\n",
       "   'Variant Annotation ID': 1449169911,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 15.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'SCAR, MPE, SJS (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.06,\n",
       "   'Allele Of Frequency In Cases': '*35:08',\n",
       "   'Frequency In Controls': 0.001,\n",
       "   'Allele Of Frequency In Controls': '*35:08',\n",
       "   'P Value': '= 0.231',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 10.45,\n",
       "   'Confidence Interval Start': 0.4,\n",
       "   'Confidence Interval Stop': 270.41,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449170027,\n",
       "   'Variant Annotation ID': 1449169930,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 15.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'SCAR, MPE or SJS (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.13,\n",
       "   'Allele Of Frequency In Cases': '*39:01',\n",
       "   'Frequency In Controls': 0.02,\n",
       "   'Allele Of Frequency In Controls': '*39:01',\n",
       "   'P Value': '= 0.131',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 7.54,\n",
       "   'Confidence Interval Start': 0.63,\n",
       "   'Confidence Interval Stop': 89.76,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449169870,\n",
       "   'Variant Annotation ID': 1449169849,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 10.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced MPE (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.5,\n",
       "   'Allele Of Frequency In Cases': '*15:02',\n",
       "   'Frequency In Controls': 0.12,\n",
       "   'Allele Of Frequency In Controls': '*15:02',\n",
       "   'P Value': '= 0.005',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 7.33,\n",
       "   'Confidence Interval Start': 1.63,\n",
       "   'Confidence Interval Stop': 33.02,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449169858,\n",
       "   'Variant Annotation ID': 1449169849,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 15.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced SCAR, SJS, MPE (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.024,\n",
       "   'Allele Of Frequency In Cases': '*15:02',\n",
       "   'Frequency In Controls': 0.12,\n",
       "   'Allele Of Frequency In Controls': '*15:02',\n",
       "   'P Value': '= 0.04',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 4.89,\n",
       "   'Confidence Interval Start': 1.28,\n",
       "   'Confidence Interval Stop': 18.66,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449170040,\n",
       "   'Variant Annotation ID': 1449169849,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 5.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced SCAR',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.2,\n",
       "   'Allele Of Frequency In Cases': '*15:02',\n",
       "   'Frequency In Controls': 0.12,\n",
       "   'Allele Of Frequency In Controls': '*15:02',\n",
       "   'P Value': '= 0.508',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 1.83,\n",
       "   'Confidence Interval Start': 0.18,\n",
       "   'Confidence Interval Stop': 19.25,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449169905,\n",
       "   'Variant Annotation ID': 1449169896,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 10.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced MPE (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.3,\n",
       "   'Allele Of Frequency In Cases': '*44:03',\n",
       "   'Frequency In Controls': 0.04,\n",
       "   'Allele Of Frequency In Controls': '*44:03',\n",
       "   'P Value': '= 0.029',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 10.29,\n",
       "   'Confidence Interval Start': 1.45,\n",
       "   'Confidence Interval Stop': 72.81,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449169842,\n",
       "   'Variant Annotation ID': 1449169831,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 15.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced SCAR, SJS or MPE (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.33,\n",
       "   'Allele Of Frequency In Cases': '*02:07',\n",
       "   'Frequency In Controls': 0.06,\n",
       "   'Allele Of Frequency In Controls': '*02:07',\n",
       "   'P Value': '= 0.013',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 7.83,\n",
       "   'Confidence Interval Start': 1.6,\n",
       "   'Confidence Interval Stop': 38.25,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449170031,\n",
       "   'Variant Annotation ID': 1449169831,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 10.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced MPE',\n",
       "   'Characteristics Type': 'Drug',\n",
       "   'Frequency In Cases': 0.3,\n",
       "   'Allele Of Frequency In Cases': '*02:07',\n",
       "   'Frequency In Controls': 0.06,\n",
       "   'Allele Of Frequency In Controls': '*02:07',\n",
       "   'P Value': '= 0.052',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 6.71,\n",
       "   'Confidence Interval Start': 1.13,\n",
       "   'Confidence Interval Stop': 40.07,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449170033,\n",
       "   'Variant Annotation ID': 1449169831,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 5.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced SCAR',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.4,\n",
       "   'Allele Of Frequency In Cases': '*02:07',\n",
       "   'Frequency In Controls': 0.22,\n",
       "   'Allele Of Frequency In Controls': '*02:07',\n",
       "   'P Value': '= 0.060',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 10.44,\n",
       "   'Confidence Interval Start': 1.23,\n",
       "   'Confidence Interval Stop': 88.44,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449169890,\n",
       "   'Variant Annotation ID': 1449169878,\n",
       "   'Study Type': 'case series',\n",
       "   'Study Cases': 10.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced MPE (cases and controls)',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.7,\n",
       "   'Allele Of Frequency In Cases': '*33:03',\n",
       "   'Frequency In Controls': 0.22,\n",
       "   'Allele Of Frequency In Controls': '*33:03',\n",
       "   'P Value': '= 0.005',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 8.27,\n",
       "   'Confidence Interval Start': 1.83,\n",
       "   'Confidence Interval Stop': 37.41,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301},\n",
       "  {'Study Parameters ID': 1449170038,\n",
       "   'Variant Annotation ID': 1449169878,\n",
       "   'Study Type': 'case/control',\n",
       "   'Study Cases': 5.0,\n",
       "   'Study Controls': 50.0,\n",
       "   'Characteristics': 'LTG-induced SCAR',\n",
       "   'Characteristics Type': 'Disease',\n",
       "   'Frequency In Cases': 0.0,\n",
       "   'Allele Of Frequency In Cases': '*33:03',\n",
       "   'Frequency In Controls': 0.22,\n",
       "   'Allele Of Frequency In Controls': '*33:03',\n",
       "   'P Value': '= 0.570',\n",
       "   'Ratio Stat Type': 'OR',\n",
       "   'Ratio Stat': 0.31,\n",
       "   'Confidence Interval Start': 0.02,\n",
       "   'Confidence Interval Stop': 6.08,\n",
       "   'Biogeographical Groups': 'East Asian',\n",
       "   'PMID': 29238301}],\n",
       " 'var_drug_ann': [],\n",
       " 'var_fa_ann': [],\n",
       " 'var_pheno_ann': [{'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169911,\n",
       "   'Variant/Haplotypes': 'HLA-B*35:08',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).',\n",
       "   'Sentence': 'HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*35:08',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169930,\n",
       "   'Variant/Haplotypes': 'HLA-B*39:01',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'no',\n",
       "   'Notes': 'The allele was not significant when comparing allele frequency in cases of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (2/15) and controls (controls were individuals without AEs who took lamotrigine)(1/50) both on lamotrigine.',\n",
       "   'Sentence': 'HLA-B *39:01 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*39:01',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169849,\n",
       "   'Variant/Haplotypes': 'HLA-B*15:02',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was a significant difference in allele frequency when comparing incidence of LTG-induced severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE) and controls (individuals without AEs who took lamotrigine). There was also a significant difference when only considering MPE. The allele was more frequent in cases of MPE (6/15) than in controls (6/50).',\n",
       "   'Sentence': 'HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*15:02',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Side Effect:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169896,\n",
       "   'Variant/Haplotypes': 'HLA-B*44:03',\n",
       "   'Gene': 'HLA-B',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was significantly different when comparing between cases of LTG-induced MPE (3/10) and controls (individuals without AEs who took lamotrigine) (2/50).',\n",
       "   'Sentence': 'HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*44:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169831,\n",
       "   'Variant/Haplotypes': 'HLA-A*02:07',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'The allele was more frequent in cases (5/15) than in controls (3/50). The allele was only significant when the authors group together severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome or Maculopapular Exanthema (MPE). The allele was not significantly associated with MPE, SCAR or SJS alone.',\n",
       "   'Sentence': 'HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*02:07',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'risk of',\n",
       "   'Phenotype': 'Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1449169878,\n",
       "   'Variant/Haplotypes': 'HLA-A*33:03',\n",
       "   'Gene': 'HLA-A',\n",
       "   'Drug(s)': 'lamotrigine',\n",
       "   'PMID': 29238301,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': 'There was no significant difference in allele frequency when comparing between individuals who experienced lamotrigine induced severe cutaneous adverse reactions (SCAR), maculopapular exanethema (MPE), or Stevens Johnson Syndrome (SJS) (7/15) versus controls (took lamotrigine without AEs) (11/50) but was significant when comparing cases of LTG-induced MPE (7/10) and controls (11/50). It was not associated with SCAR.',\n",
       "   'Sentence': 'HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.',\n",
       "   'Alleles': '*33:03',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'likelihood of',\n",
       "   'Phenotype': 'Disease:Maculopapular Exanthema',\n",
       "   'Multiple phenotypes And/or': 'or',\n",
       "   'When treated with/exposed to/when assayed with': 'when exposed to',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Disease:Epilepsy',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan}]}"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "annotations_pmid_grouped[29238301]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Save annotations_pmid_grouped to json\n",
    "with open(\"data/variantAnnotations/exploration/annotations_pmid_grouped_2.json\", \"w\") as f:\n",
    "    json.dump(annotations_pmid_grouped, f, indent=2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of pmids in annotations_pmid_grouped: 2864\n",
      "Number of pmids in annotations_by_pmcid: 13523\n",
      "Number of pmids in annotations_by_pmcid: 13523\n"
     ]
    }
   ],
   "source": [
    "# Check number of pmids in annotations_pmid_grouped\n",
    "print(f\"Number of pmids in annotations_pmid_grouped: {len(annotations_pmid_grouped)}\")\n",
    "# Check number of pmids in annotations_by_pmcid\n",
    "print(f\"Number of pmids in annotations_by_pmcid: {len(annotations_by_pmcid)}\")\n",
    "# Check number of pmids in annotations_by_pmcid\n",
    "print(f\"Number of pmids in annotations_by_pmcid: {len(annotations_by_pmcid)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'pmid': 39528547,\n",
       " 'pmcid': 'PMC11554802',\n",
       " 'title': 'Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis',\n",
       " 'study_parameters': {'Study Parameters ID': 1453086511,\n",
       "  'Variant Annotation ID': 1453086503,\n",
       "  'Study Type': 'meta-analysis',\n",
       "  'Study Cases': 1138.0,\n",
       "  'Study Controls': nan,\n",
       "  'Characteristics': 'Grade 3/4 Neutropenia, 5 studies',\n",
       "  'Characteristics Type': 'Study Cohort',\n",
       "  'Frequency In Cases': nan,\n",
       "  'Allele Of Frequency In Cases': nan,\n",
       "  'Frequency In Controls': nan,\n",
       "  'Allele Of Frequency In Controls': nan,\n",
       "  'P Value': '= 0.05',\n",
       "  'Ratio Stat Type': nan,\n",
       "  'Ratio Stat': nan,\n",
       "  'Confidence Interval Start': nan,\n",
       "  'Confidence Interval Stop': nan,\n",
       "  'Biogeographical Groups': 'Multiple groups',\n",
       "  'PMID': 39528547},\n",
       " 'var_drug_ann': [],\n",
       " 'var_fa_ann': [],\n",
       " 'var_pheno_ann': [{'Variant Annotation ID': 1453086503,\n",
       "   'Variant/Haplotypes': 'UGT1A1*1, UGT1A1*28',\n",
       "   'Gene': 'UGT1A1',\n",
       "   'Drug(s)': 'sacituzumab govitecan',\n",
       "   'PMID': 39528547,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'yes',\n",
       "   'Notes': '\"Genotype-specific analyses revealed higher incidence of grade 3–4 neutropenia in patients with heterozygous and homozygous variant genotypes versus wild type group. Severe neutropenia occurred in 67% of homozygous carriers versus 44% from wild type and 50% from heterozygous groups respectively (P\\u2009=\\u20090.05, Supplementary Table 3). \"',\n",
       "   'Sentence': 'UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Neutropenia when treated with sacituzumab govitecan in people with Breast Neoplasms as compared to UGT1A1 *1/*1.',\n",
       "   'Alleles': '*1/*28 + *28/*28',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': nan,\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': 'increased',\n",
       "   'Side effect/efficacy/other': 'severity of',\n",
       "   'Phenotype': 'Side Effect:Neutropenia',\n",
       "   'Multiple phenotypes And/or': nan,\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': 'in people with',\n",
       "   'Population Phenotypes or diseases': 'Other:Breast Neoplasms',\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': '*1/*1',\n",
       "   'Comparison Metabolizer types': nan}]}"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "annotations_by_pmcid[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "sorted_annotations_by_pmcid = sorted(annotations_by_pmcid, key=lambda x: x[\"pmid\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'pmid': 990860,\n",
       " 'pmcid': 'PMC1689719',\n",
       " 'title': 'Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency',\n",
       " 'study_parameters': {'Study Parameters ID': 1184521221,\n",
       "  'Variant Annotation ID': 1184521219,\n",
       "  'Study Type': 'cohort',\n",
       "  'Study Cases': 8.0,\n",
       "  'Study Controls': nan,\n",
       "  'Characteristics': 'Red blood cells from G6PD deficient individuals classified as having the Canton variant or Hong Kong-Pokfulam variant.',\n",
       "  'Characteristics Type': 'Study Cohort',\n",
       "  'Frequency In Cases': nan,\n",
       "  'Allele Of Frequency In Cases': nan,\n",
       "  'Frequency In Controls': nan,\n",
       "  'Allele Of Frequency In Controls': nan,\n",
       "  'P Value': nan,\n",
       "  'Ratio Stat Type': 'OR',\n",
       "  'Ratio Stat': nan,\n",
       "  'Confidence Interval Start': nan,\n",
       "  'Confidence Interval Stop': nan,\n",
       "  'Biogeographical Groups': 'East Asian',\n",
       "  'PMID': 990860},\n",
       " 'var_drug_ann': [],\n",
       " 'var_fa_ann': [],\n",
       " 'var_pheno_ann': [{'Variant Annotation ID': 1184521237,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'phenytoin',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is not associated with Hemolysis when treated with phenytoin.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184519163,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'primaquine',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from 10 G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment. Primaquine treatment was associated with decreased half life in all cases, shortening it to 3-5 days. *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is associated with Hemolysis when treated with primaquine.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521196,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'chloramphenicol',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is not associated with Hemolysis when treated with chloramphenicol.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521202,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'aminosalicylic acid, isoniazid, streptomycin',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*. 4-Aminosalicylic acid = PAS.',\n",
       "   'Sentence': 'G6PD deficiency is not associated with Hemolysis when treated with aminosalicylic acid, isoniazid or streptomycin.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': 'or',\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521224,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'levodopa',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is not associated with Hemolysis when treated with levodopa.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521219,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'trimethoprim',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is not associated with Hemolysis when treated with trimethoprim.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521208,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'menadione sodium bisulfite',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- menaphthone sodium bisulphite (Hykinone) treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with menadione sodium bisulfite.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521229,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'trihexyphenidyl',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- benzhexol treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with trihexyphenidyl.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521141,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'sulfamethoxazole',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'in some but not all cases. Red blood cells from 12 G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment. Only in 4 cases was the half life shortened by sulphamethoxazole treatment. *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is associated with Hemolysis when treated with sulfamethoxazole.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521135,\n",
       "   'Variant/Haplotypes': 'G6PD deficiency',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'nitrofurantoin',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from 3 G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment. Nitrofurantoin treatment was associated with decreased half life in all cases, shortening it to 4-14 days. *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD deficiency is associated with Hemolysis when treated with nitrofurantoin.',\n",
       "   'Alleles': nan,\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521157,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'proguanil',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from a G6PD deficient patient were labelled with 51-Cr and cross-transfused into a G6PD-normal male recipient. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with proguanil.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521147,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'chloroquine',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from a G6PD deficient patient were labelled with 51-Cr and cross-transfused into a G6PD-normal male recipient. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with chloroquine.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521173,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'phenylbutazone',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with phenylbutazone.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521162,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'pyrimethamine',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from a G6PD deficient patient were labelled with 51-Cr and cross-transfused into a G6PD-normal male recipient. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with pyrimethamine.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521179,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'colchicine, probenecid',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with colchicine or probenecid.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': 'or',\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan},\n",
       "  {'Variant Annotation ID': 1184521167,\n",
       "   'Variant/Haplotypes': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Gene': 'G6PD',\n",
       "   'Drug(s)': 'acetaminophen',\n",
       "   'PMID': 990860,\n",
       "   'Phenotype Category': 'Toxicity',\n",
       "   'Significance': 'not stated',\n",
       "   'Notes': 'Red blood cells from a G6PD deficient patient were labelled with 51-Cr and cross-transfused into a G6PD-normal male recipient. The half-life of these labelled red blood cells was determined before and after drug treatment- paracetamol treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.',\n",
       "   'Sentence': 'G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is not associated with Hemolysis when treated with acetaminophen.',\n",
       "   'Alleles': 'Canton, Taiwan-Hakka, Gifu-like, Agrigento-like',\n",
       "   'Specialty Population': nan,\n",
       "   'Metabolizer types': 'deficiency',\n",
       "   'isPlural': 'Is',\n",
       "   'Is/Is Not associated': 'Not associated with',\n",
       "   'Direction of effect': nan,\n",
       "   'Side effect/efficacy/other': nan,\n",
       "   'Phenotype': 'Side Effect:Hemolysis',\n",
       "   'Multiple phenotypes And/or': 'and',\n",
       "   'When treated with/exposed to/when assayed with': 'when treated with',\n",
       "   'Multiple drugs And/or': nan,\n",
       "   'Population types': nan,\n",
       "   'Population Phenotypes or diseases': nan,\n",
       "   'Multiple phenotypes or diseases And/or': nan,\n",
       "   'Comparison Allele(s) or Genotype(s)': nan,\n",
       "   'Comparison Metabolizer types': nan}]}"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sorted_annotations_by_pmcid[5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "default",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
